16.95
+0.02(+0.12%)
Currency In USD
| Previous Close | 16.93 |
| Open | 16.93 |
| Day High | 17.18 |
| Day Low | 16.68 |
| 52-Week High | 21.71 |
| 52-Week Low | 3.42 |
| Volume | 665,491 |
| Average Volume | 1.2M |
| Market Cap | 784.18M |
| PE | -5.54 |
| EPS | -3.06 |
| Moving Average 50 Days | 18.5 |
| Moving Average 200 Days | 13.08 |
| Change | 0.02 |
If you invested $1000 in UroGen Pharma Ltd. (URGN) since IPO date, it would be worth $1,212.45 as of October 19, 2025 at a share price of $16.95. Whereas If you bought $1000 worth of UroGen Pharma Ltd. (URGN) shares 5 years ago, it would be worth $738.56 as of October 19, 2025 at a share price of $16.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
GlobeNewswire Inc.
Oct 02, 2025 12:00 PM GMT
PRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty cancers, today announced the publication of a compre
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Sep 08, 2025 12:00 PM GMT
PRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of ind
UroGen Pharma to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 21, 2025 12:00 PM GMT
PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will parti